Related Experiment Videos
Tissue-engineered bioprosthetic venous valve: a long-term study in sheep
O E Teebken1, C Puschmann, T Aper
1Division of Thoracic and Cardiovascular Surgery, Hannover Medical School, Hannover, Germany.
Summary
Tissue-engineered venous valves (TE grafts) were developed using decellularized ovine veins and patient cells. These TE grafts showed promising results for treating chronic venous insufficiency, demonstrating immunological acceptance and valve competence in sheep models.
Area of Science:
- Vascular Surgery
- Tissue Engineering
- Immunology
Background:
- Chronic venous insufficiency (CVI) significantly impacts patient quality of life.
- Current treatments for CVI often involve invasive procedures with limited long-term efficacy.
- Restoring native venous valve function is a key challenge in CVI treatment.
Purpose of the Study:
- To develop an immunologically tolerated, tissue-engineered venous valve (TE graft).
- To evaluate the incorporation and function of TE grafts in native vessels.
- To assess the potential of TE grafts for treating chronic venous insufficiency.
Main Methods:
- Decellularized allogeneic ovine veins were used as a scaffold.
- Scaffolds were repopulated with recipient's myofibroblasts (MFB) and endothelial cells (EC).
- TE grafts were implanted into the external jugular vein of sheep, with autografts serving as controls.
Main Results:
- Successful repopulation of the matrix with MFB and EC was achieved.
- TE grafts demonstrated patency rates of 44%, 44%, and 34% at 1, 6, and 12 weeks, respectively.
- Most TE grafts exhibited competent valves, with minor inflammatory reactions and no significant difference from autografts, except for neo-intima formation causing reflux in some cases.
Conclusions:
- Acellularization and in vitro autogeneic re-seeding of venous conduits can create immunologically acceptable implants.
- Tissue-engineered venous grafts show potential for restoring venous valve function.
- Further research is needed to optimize TE grafts and mitigate issues like neo-intima formation for effective CVI treatment.